Small Cap Stocks To Follow Now - May 3rd

Key Points

• Inflection Point Acquisition Corp. II (IPXX), Direxion Daily MU Bull 2X Shares (MUU), and Cue Biopharma (CUE) were flagged by MarketBeat's screener as the small‑cap stocks with the highest recent dollar trading volume.
• Small‑cap stocks—typically about $300 million to $2 billion in market capitalization—can offer higher growth potential but come with greater volatility and lower liquidity than mid‑ or large‑caps.
• Cue Biopharma is a clinical‑stage biopharmaceutical company whose lead candidate, CUE‑101, is being developed to treat HPV16+ recurrent/metastatic head and neck cancer.

Inflection Point Acquisition Corp. II, Direxion Daily MU Bull 2X Shares, and Cue Biopharma are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of publicly traded companies with relatively small market capitalizations—typically roughly $300 million to $2 billion, though exact cutoffs vary by index and provider. Investors view them as having higher growth potential but also greater volatility and lower liquidity compared with mid- and large-cap stocks. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

Inflection Point Acquisition Corp. II (IPXX)

Read Our Latest Research Report on IPXX

Direxion Daily MU Bull 2X Shares (MUU)

Read Our Latest Research Report on MUU

Cue Biopharma (CUE)

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.

Read Our Latest Research Report on CUE

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.